In-Vivo CAR-T for Autoimmune Disease: Clinical Applications and Future Directions

Abstract

In-vivo chimeric antigen receptor T-cell (CAR-T) therapy is rapidly emerging as a transformative therapeutic modality for autoimmune diseases. Unlike conventional ex-vivo CAR-T protocols, in-vivo approaches seek to engineer T cells directly within the patient, offering new opportunities to modulate aberrant immune responses. This review synthesizes recent clinical and translational research on in-vivo CAR-T for autoimmune indications, discussing its mechanistic rationale, current evidence base, clinical outcomes, and guideline perspectives. The article emphasizes the potential of in-vivo CAR-T to address unmet needs in refractory autoimmune conditions, explores associated risks, and outlines future research directions to optimize safety, efficacy, and implementation in clinical practice.

Introduction

Autoimmune diseases are characterized by dysregulated immune responses that target self-antigens, leading to persistent inflammation and tissue destruction. Despite advances in immunosuppressants and biologics, a significant proportion of patients exhibit refractory disease or experience relapses. Traditional therapies often compromise host immunity, increasing infection risk and malignancy. CAR-T cell therapies, originally developed for hematologic malignancies, are now being repurposed for autoimmune disease, with a focus on in-vivo engineering to overcome limitations of ex-vivo manufacturing. In-vivo CAR-T platforms promise streamlined production, reduced costs, and enhanced scalability, potentially revolutionizing the therapeutic landscape for autoimmune disorders.

Epidemiology / Disease Burden

Autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS), collectively affect millions worldwide, imposing substantial morbidity and healthcare burden. Epidemiological studies estimate that up to 5-8% of the global population is affected by at least one autoimmune condition. Patients with refractory or relapsing disease face increased disability, reduced quality of life, and higher healthcare utilization. There remains a critical unmet need for targeted, durable, and less toxic therapies that can induce lasting remission without compromising immune surveillance.

Pathophysiology

The pathogenesis of autoimmune diseases involves loss of tolerance to self-antigens, expansion of autoreactive lymphocytes, and chronic inflammation. B cells and T cells play central roles, with autoantibody production and cytotoxic activity contributing to tissue injury. Cytokine dysregulation and genetic predisposition further modulate disease susceptibility. CAR-T cell therapy leverages synthetic biology to redirect T cells toward pathogenic cell populations, such as autoreactive B cells, offering the potential to reset immune homeostasis. In-vivo CAR-T strategies utilize targeted gene delivery systems typically viral vectors or lipid nanoparticles to transduce endogenous T cells with CAR constructs, enabling them to eliminate disease-mediating cells in situ.

Risk Factors

Risk factors for autoimmune diseases include genetic susceptibility (e.g., HLA haplotypes), environmental triggers (infections, drugs, toxins), hormonal influences, and epigenetic modifications. Disease severity and response to therapy are further modulated by age, sex, comorbidities, and prior treatment history. For in-vivo CAR-T therapy, patient-specific factors such as immune status, T cell repertoire, and history of immunosuppression may influence efficacy and safety. Identifying biomarkers for patient selection and risk stratification is an area of active investigation.

Clinical Features

Clinical manifestations of autoimmune diseases vary widely, from organ-specific symptoms (e.g., nephritis in SLE) to systemic features (fevers, fatigue, cytopenias). Disease flares, refractory symptoms, and extra-articular involvement contribute to disease complexity and therapeutic challenges. For clinicians considering in-vivo CAR-T, careful phenotyping of disease activity, immune cell profiles, and prior treatment responses is essential to guide patient selection and monitoring.

Diagnosis

Diagnosis of autoimmune diseases relies on clinical assessment, serological markers (e.g., ANA, RF, anti-dsDNA), and imaging or tissue biopsy where indicated. Flow cytometry and molecular assays allow detailed characterization of lymphocyte subsets, relevant for identifying therapeutic targets. For in-vivo CAR-T trials, baseline immune profiling and longitudinal monitoring are critical for assessing treatment impact and early detection of adverse events.

Treatment & Management

Standard management includes corticosteroids, DMARDs, biologics (e.g., anti-TNF, anti-CD20), and small molecule inhibitors. However, these approaches may be insufficient in severe or refractory cases and often require chronic administration with cumulative toxicity. In-vivo CAR-T therapy represents a paradigm shift by enabling in-situ generation of therapeutic T cells capable of selectively depleting pathogenic populations. Early-phase studies have targeted CD19+ B cells in SLE and other autoimmune diseases, achieving profound disease remission in a subset of patients. Safety considerations include cytokine release syndrome (CRS), neurotoxicity, and risk of prolonged immunosuppression.

Recent Advances / Emerging Therapies

Recent advances include the development of novel vectors for targeted in-vivo delivery, improved CAR constructs with enhanced specificity and safety switches, and integration with gene editing technologies (e.g., CRISPR/Cas9). Preclinical and early-phase clinical studies have demonstrated the feasibility of in-vivo CAR-T for autoimmune indications, with promising efficacy and manageable toxicity profiles. Combination strategies, such as in-vivo CAR-T with immune tolerance induction or checkpoint inhibition, are being explored to enhance durability and minimize relapse. Ongoing trials in refractory SLE, MS, and autoimmune cytopenias are expected to shape the future standard of care.

Guideline Recommendations

Guidelines for in-vivo CAR-T in autoimmune disease are still evolving, with current recommendations emphasizing careful patient selection, risk mitigation strategies, and multidisciplinary management. Regulatory agencies and expert panels endorse participation in clinical trials and recommend robust long-term follow-up to monitor for delayed toxicities, including secondary malignancies or opportunistic infections. Consensus is emerging around the need for harmonized outcome measures, standardized monitoring protocols, and real-world data collection to inform guideline updates as the evidence base matures.

Conclusion

In-vivo CAR-T therapy represents a promising frontier in the management of refractory autoimmune diseases, offering the potential for targeted, durable, and scalable immunomodulation. While early results are encouraging, further research is needed to refine delivery systems, optimize patient selection, and ensure long-term safety. As the field evolves, integration of in-vivo CAR-T into clinical algorithms will require multidisciplinary collaboration, robust evidence generation, and ongoing guideline development to maximize patient benefit and minimize risk.